Myasthenia gravis and coronavirus disease 2019: A report from Iran

Area of Science:

• Neurology
• Infectious Diseases
• Immunology

Background:

• Coronavirus disease 2019 (COVID-19) is a global pandemic with significant mortality.
• Comorbidities can worsen COVID-19 outcomes.
• Myasthenia gravis (MG), a neuromuscular junction disorder, theoretically poses a risk for severe COVID-19 due to respiratory compromise.

Purpose of the Study:

• To investigate the pattern of COVID-19 infection in patients with myasthenia gravis.
• To assess if MG patients exhibit increased susceptibility or severity of COVID-19.
• To evaluate the influence of age, thymectomy status, and disease duration on COVID-19 outcomes in MG patients.

Main Methods:

• A prospective cohort study involving 150 patients with myasthenia gravis.
• Monitoring participants for six months for signs and symptoms of COVID-19 infection.
• Comparative analysis between COVID-19 infected MG patients and non-infected MG patients.

Main Results:

• No statistically significant difference in COVID-19 susceptibility was observed between MG patients and controls.
• COVID-19 severity in MG patients was not found to be increased based on age, duration of MG, or thymectomy status.
• Analysis did not reveal a correlation between MG clinical status and COVID-19 outcomes.

Conclusions:

• Myasthenia gravis does not appear to confer increased susceptibility or severity to COVID-19.
• Factors such as age, thymectomy status, and disease duration did not influence COVID-19 outcomes in the studied MG population.
• These findings suggest that MG patients may not require specific COVID-19 management adjustments beyond general recommendations.